Venture Catalysts invests in USD 1 million seed funding round for a biotech startup Cellivate Technologies. Antler led the round. Hatcher+ and We Founders Circle also invested in Cellivate Technologies to capitalise on the rapidly growing cell culture market, especially concerning microcarriers and serum, which is expected to reach USD 33 billion by 2030.
Operating at the intersection of biotech and health tech, Cellivate Technologies is developing innovative solutions to address critical challenges in cell culture and biomanufacturing.
Viknish Krishnan-Kutty, founder and CEO of Cellivate Technologies, brings a wealth of expertise to the venture. With a B.Eng from the State University of New York - Stony Brook and a PhD from the National University of Singapore, Krishnan-Kutty's background as a postdoctoral research fellow at the National University of Singapore and The Agency for Science, Technology, and Research (A*STAR) has been instrumental in shaping the core expertise of Prof. Thirumalai Venky Venkatesan, a professor at the University of Oklahoma and a prolific inventor and serial entrepreneur, further strengthens Cellivate Technologies. His involvement adds significant value to the company's scientific rigor and commercial prospects.
Commenting on the investment, Apoorva Ranjan Sharma, Co-founder, and Managing Director of Venture Catalysts++ said, “The groundbreaking work of Cellivate Technologies in cell culture technology has the potential to significantly accelerate research and development across various fields, from drug discovery to regenerative medicine. The global impact of more efficient and ethical cell culture processes cannot be overstated. We are thrilled to support Dr. Krishnan-Kutty and his team in their mission to transform the landscape of cell culture and biomanufacturing. This investment aligns perfectly with our strategy of backing visionary startups that have the potential to drive paradigm shifts in critical industries. We believe Cellivate Technologies is not just creating products but pioneering a new era in biotechnology that will have far-reaching implications for human health and scientific progress.”
The seed funding will enable Cellivate Technologies to accelerate its R&D efforts, scale up production of its innovative products, and expand its market reach. The company's B2B business model positions it to serve various clients in the biotech and pharmaceutical industries, research institutions, and beyond. The investment underscores Venture Catalysts' commitment to supporting cutting-edge technologies with the potential to drive significant advancements in critical sectors. By backing Cellivate Technologies, Venture Catalysts is investing in the future of biotech and health tech innovation.
